Teva Announces COPAXONE® Recognized As “Brand Of The Year” By Pharmaceutical Executive Magazine
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that
® (glatiramer acetate injection), the #1 global
therapy for relapsing multiple sclerosis, has been named the 2014
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that COPAXONE ® (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 “Brand of The Year” by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry. “Teva and the COPAXONE ® team are honored to be acknowledged by Pharmaceutical Executive, a respected voice in our industry,” said Mike Derkacz, Vice President, and General Manager of Teva CNS. “The award is a tribute to the hard work of Teva employees and scientists throughout the years; the growth of COPAXONE ® and the loyalty of prescribers and patients alike; and speaks to the product’s benefits, tolerability and safety." The “Brand of The Year” award was received on behalf of Teva by John Hassler, Vice President of Marketing for Teva CNS at an award ceremony hosted by Pharmaceutical Executive in New York. “For more than 20 years, Teva has consistently focused on making this brand an appropriate choice for many patients with relapsing forms of multiple sclerosis with rigorous clinical studies, product enhancements and patient support services like Shared Solutions ®. Our most recent and significant product development is the new FDA approved, three-times-a-week dose of COPAXONE ® 40mg. This honor is a testament to that work,” he said. COPAXONE ® was first approved for marketing by the U.S. FDA as a treatment for relapsing-remitting multiple sclerosis in 1996. Daily COPAXONE ® 20 mg/mL is approved in more than 50 countries worldwide, including the United States, all European countries, Israel, Canada, Mexico, Australia and Russia. On January 28, 2014, Teva announced that the U.S. Food and Drug Administration approved the Company’s supplemental new drug application (sNDA) for three-times-a-week COPAXONE ® 40 mg/mL, a new dose of COPAXONE ®. This new formulation allows for a less-frequent subcutaneous dosing regimen as compared to the COPAXONE ® 20 mg/mL daily dose option. About COPAXONE® COPAXONE ® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE ® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. See additional important information at: www.CopaxonePrescribingInformation.com. For hardcopy releases, please see enclosed full prescribing information. COPAXONE ® is now approved in more than 50 countries worldwide, including the United States, all European countries, Israel, Canada, Mexico, Australia and Russia. Important Safety Information about COPAXONE® Patients allergic to glatiramer acetate or mannitol should not take COPAXONE ®. Some patients report a short-term reaction right after injecting COPAXONE ®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, patients should call the emergency phone number in their area. Patients should call their doctor right away if they develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, patients should not give themselves any more injections until their doctor tells them to begin again. Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. Patients may experience more than one such episode, usually beginning at least one month after starting treatment. Patients should tell their doctor if they experience chest pain that lasts for a long time or feels very intense. A permanent indentation under the skin (lipoatrophy or, rarely, necrosis) at the injection site may occur, due to local destruction of fat tissue. Patients should follow proper injection technique and inform their doctor of any skin changes. The most common side effects of COPAXONE ® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE ®. For a complete list, patients should ask their doctor or pharmacist. Patients should tell their doctor about any side effects they have while taking COPAXONE ®. Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. About Teva Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Teva's Specialty Medicines businesses focus on CNS, respiratory oncology, pain, and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.